Health Care & Life Sciences » Pharmaceuticals | Chugai Pharmaceutical Co. Ltd.

Chugai Pharmaceutical Co. Ltd. | Key People and Executives

Osamu Nagayama
Chairman
Tatsuro Kosaka
President, CEO & Representative Director
Sophie Kornowski-Bonnet
Director
Christoph Franz
Director
Daniel O'Day
Director
Motoo Ueno
Vice Chairman, Head-Audit & CSR Promotions
Yoichiro Ichimaru
Independent Outside Director
Masayuki Oku
Independent Outside Director
Yasuo Ikeda
Independent Outside Director
Osamu Nagayama
Chairman
Tatsuro Kosaka
President, CEO & Representative Director
Itagaki Toshiaki
CFO, Manager-Information Technology & Accounting
Hisanori Takanashi
Manager-R&D Portfolio Management Department
Hisafumi Okabe
Senior Executive Officer & Head-Research
Mikio Sakai
TECENTRIQ Lifecycle Leader
Hitoshi Kuboniwa
Executive Officer & Head-Pharmaceuticals
Toshihiko Komori
Executive Officer
Yasushi Ito
Senior Executive Officer
Sophie Kornowski-Bonnet
Director
Christoph Franz
Director
Daniel O'Day
Director
Motoo Ueno
Vice Chairman, Head-Audit & CSR Promotions
Susumu Kato
Senior Executive Officer & General Manager-Sales
Mamoru Togashi
Auditor
Shunji Yokoyama
Auditor
Koki Harada
Head-Media Relations Group
Keiji Kono
Senior Executive Officer & Head-External Affairs
Toshiya Sasai
Head-Investor Relations Group
Shinya Unno
Secretary & Personnel Manager
Junichi Ebihara
Senior Executive Officer & Manager-Legal Affairs
Yoichiro Ichimaru
Independent Outside Director
Masayuki Oku
Independent Outside Director
Yasuo Ikeda
Independent Outside Director

About Chugai Pharmaceutical Co.

View Profile
Address
Nihonbashi Mitsui Tower, 15/F
Tokyo Tokyo 103
Japan
Employees -
Website http://www.chugai-pharm.co.jp
Updated 07/08/2019
Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of the pharmaceuticals. Its operations are carried out through the following business divisions: Research, Development, Production, Marketing, Medical Affairs and Drug Safety. The Research division focuses its efforts on creating innovative drugs by using its competitive strengths that include proprietary antibody technologies and cutting-edge research resources.